Biomerica's HP+Detect™ Gains MHRA Approval, Opening Great Britain Market
summarizeSummary
Biomerica Inc. has received MHRA (Medicines and Healthcare products Regulatory Agency) registration for its HP+Detect™ product, enabling commercial sales in Great Britain. This regulatory approval is a significant positive development for the micro-cap company, especially considering its recent 'going concern' warning and declining revenue as highlighted in its January 10-Q filing. Gaining access to the Great Britain market provides a crucial new potential revenue stream for a company facing significant liquidity challenges. Traders will now closely monitor for updates on sales traction and the financial impact of this market expansion.
في وقت هذا الإعلان، كان BMRA يتداول عند ٢٫٠٨ US$ في NASDAQ ضمن قطاع Life Sciences، مع قيمة سوقية تقارب ٦٫١ مليون US$. تراوح نطاق التداول خلال 52 أسبوعًا بين ١٫٨٨ US$ و٥٫٩٢ US$. تم تقييم هذا الخبر على أنه ذو معنويات سوقية إيجابية وبدرجة أهمية ٧ من 10. المصدر: Reuters.